Back to top
more

Apyx Medical (APYX)

(Delayed Data from NSDQ)

$1.96 USD

1.96
81,711

-0.08 (-3.92%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $1.99 +0.03 (1.53%) 4:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

What Makes Apyx (APYX) a New Buy Stock

by Zacks Equity Research

Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Apyx Medical (APYX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Apyx (APYX) delivered earnings and revenue surprises of 27.78% and 7.67%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Apyx Medical (APYX) Q2 Earnings Expected to Decline

by Zacks Equity Research

Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Apyx Medical (APYX) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Apyx Medical (APYX) likely to gain from J-plasma technology in Q1; margins under pressure.

Zacks Equity Research

Apyx Medical (APYX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Apyx Medical (APYX) closed at $6.31, marking a -0.63% move from the previous day.

Zacks Equity Research

Apyx Medical (APYX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Apyx Medical (APYX) closed at $7.78, marking a -0.51% move from the previous day.

Zacks Equity Research

Apyx Medical (APYX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Apyx (APYX) delivered earnings and revenue surprises of 0.00% and -1.07%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Conatus' (CNAT) Q4 Earnings Top Estimates, Emricasan in Focus

by Zacks Equity Research

Conatus (CNAT) makes an improvement with narrower-than-expected loss in the fourth quarter of 2018. Also, revenues beat mark.

Zacks Equity Research

Zimmer Biomet (ZBH) Jumps: Stock Rises 6.4%

by Zacks Equity Research

Zimmer Biomet (ZBH) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Zacks Equity Research

Has Bovie Medical (APYX) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (APYX) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Bovie Medical (APYX) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Bovie Medical (APYX) have what it takes to be a top stock pick for momentum investors? Let's find out.